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Abstract. The use of in vivo contrast-enhanced magnetic
resonance (MR) imaging as a surrogate for photosensi-
tizer (verteporfin) dosimetry in photodynamic therapy of
pancreas cancer is demonstrated by correlating MR con-
trast uptake to ex vivo fluorescence images on excised tis-
sue. An orthotopic pancreatic xenograft mouse model was
used for the study. A strong correlation (r ¼ 0.57) was
found for bulk intensity measurements of T1-weighted
gadolinium enhancement and verteporfin fluorescence in
the tumor region of interest. The use of contrast-enhanced
MR imaging shows promise as a method for treatment
planning and photosensitizer dosimetry in human photody-
namic therapy (PDT) of pancreas cancer. © The Authors.
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Photodynamic therapy (PDT) has been investigated for treat-
ment of pancreatic cancer (PaC) in a clinical trial (VERTPAC)
using the photosentizing agent verteporfin.1,2 PDT for PaC
involves the injection and uptake of verteporfin within tumor
tissue followed by activation of the drug using 690-nm light
delivered through interstitial optical fibers. One difficulty in per-
forming repeatable and accurate PDT for PaC is the highly het-
erogenous uptake of verteporfin within the tumor tissue due to
large amounts of stroma, necrotic tissue, and highly variable
vascular patterns. This creates significant challenges for the
accurate measurement of drug delivery and subsequent treatment
fiber placement. In the VERTPAC dose escalation study,1
heterogeneous response to PDTwas observed at all dose levels,
possibly due to low local concentrations of verteporfin. While
direct measurement of the photosensitizer at the site of the fiber
implantation is possible, this provides a very small data set and
incomplete information given the wide variation expected in
drug delivery. Treatment planning could be greatly enhanced
by noninvasively imaging photosensitizer distribution using
clinically relevant imaging systems that are not influenced by
tissue and blood optical properties. Here, contrast-enhanced
magnetic resonance (MR) imaging using the gadolinium
(Gd)-based contrast agent Magnevist® (Bayer Healthcare
Pharmaceuticals, Wayne, NJ) is tested as a dosimetric surrogate
for verteporfin imaging.
Both verteporfin and Magnevist® are vascular perfusion-
based molecules that at short time periods remain in normal,
healthy vasculature but perfuse into surrounding tissue in
areas with compromised blood vessels, such as tumors or tissues
with vascular diseases (retinopathy, etc.). They have similar
molecular weights (938 and 719 g∕mol for Magnevist® and
verteporfin, respectively), but their structure and distribution
phases differ significantly. According to the manufacturer’s
information sheet, Magnevist® has a distribution and elimina-
tion half-life of 0.2 0.1 and 1.6 0.1 h, respectively, and ver-
teporfin has a distribution and elimination half-life of 0.1
(calculated from Ref. 3) and 5.8 h, respectively.3,4
An orthotopic xenograft (AsPC-1) murine model (n ¼ 7) for
PaC PDTwas used in accordance with the policies and approved
protocol of the Institutional Animal Care and Use Committee
(IACUC) at Dartmouth College.5 The animals were fed a chloro-
phyll-free diet (MP Biomedicals, Solon, OH) to minimize auto-
fluorescence. The tumors were imaged after they had reached a
volume of ∼125 mm3 by measurement with externally applied
calipers. MR images were obtained using a Phillips Achieva
3.0T X-series MRI with a modified rodent coil (Philips Research
Europe, Hamburg, Germany), as previously described.5,6 Gd-
based contrast enhancement (0.03 mg∕kg, Magnevist®) was
delivered via a catheter (MTV-01, Braintree Scientific Inc.,
Braintree, MA) placed in the intraperitoneal (i.p.) cavity.
After a preliminary survey, a T2-weighted turbo spin echo
(T2W-TSE) sequence was performed in sagittal, axial, and coro-
nal imaging planes. The tumor was identified in each imaging
plane, and the best orientation for tumor resection, slicing, and
image correlation was chosen. Typically, the axial T2W-TSE
image sequence was selected for the tissue-slicing plane and
the coronal T2W-TSE was used to align the image scans
with the outermost edge of the tumor, termed the tumor origin
[Fig. 1(a)]. After the scanning slices were aligned to the tumor,
the images used for analysis were collected as follows: a T1-
weighted turbo spin echo [T1W-TSE, Fig. 1(b)] image sequence
was performed; Magnevist® was administered; a T2W-TSE
image sequence [Fig. 1(c)] was collected during contrast locali-
zation and then a postcontrast T1W-TSE [Fig. 1(d)] image
sequence was performed 10 min after injection. The T1W-
TSE contrast difference [T1W-CD=(post-Gd T1W-TSE)−
(pre-Gd T1W-TSE), Fig. 1(e)] image sequence was calculated
using the Phillips MRI software.
Verteporfin (1 mg∕kg) was administered via tail vein 60 min
prior to sacrifice and the tumor was extracted, ensuring that the
orientation of the tumor was preserved. Ex vivo tissue slices
(1 mm) were obtained using an Acrylic Adjustable Tissue
Matrix (TM S12, Braintree Scientific, Braintree, MA) andMx35
Premier Microtome Blade (Thermos Scientific, Rockford, IL)
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such that the first slice was made 1 mm from the tumor origin,
maintaining the MR image alignment. Six to eight slices were
made per tumor, for a total of 52 tissue slices. Verteporfin fluo-
rescence images were collected immediately after sectioning by
imaging the ex vivo tissue slices for each mouse on an Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE)
using the 700-nm channel and a resolution of 21 μm. After im-
aging, the tissue slices were fixed in formalin and prepared for
hematoxylin and eosin (H&E) staining (Research Pathology
Services, Dartmouth Hitchcock Medical Center, Lebanon, NH).
The verteporfin fluorescence images were compared to each
type of MR image (T1W pre-Gd, T1W post-Gd, T1WCD, and
T2W) in order to determine if a correlation existed. Regions of
interest (ROI) were demarcated using the H&E-stained tissue
and transferred to the verteporfin fluorescence and multiple
MR images using the NIH freeware ImageJ (http://rsbweb.nih
.gov/ij/, Fig. 2) and only applying an x; y-rotation of the ROI
if needed to appropriately align and measure the tumor region.
For each fluorescent and MR image, the background was sub-
tracted to remove instrumentation noise. For each corresponding
tissue slice, average pixel intensities within the ROI were deter-
mined and compared using Pearson’s product-moment correla-
tion (Fig. 3) to determine the proportional linear association.
The Pearson’s correlation coefficient, r, describes the strength
of the association where a value of 0 to 0.1, 0.1 to 0.3, 0.3 to 0.5,
and 0.5 to 1.0 indicates no, weak, medium, and strong correla-
tions, respectively, and can be negative or positive depending on
the sign. In addition, the root-mean square error (RMSE)
reported in arbitrary units of signal intensity was calculated
for each fluorescence and MR image pair and indicates the stan-
dard deviation from the best-fit line.
The T1W post-Gd images had a strong, positive linear cor-
relation (r ¼ 0.57, RMSE ¼ 128) with verteporfin fluorescence
[Fig. 3(b)] and there was a medium, positive correlation
(r ¼ 0.33, RMSE ¼ 122) between verteporfin distribution
and T1WCD MR images [Fig. 3(c)]. The RMSE of the T1W
post-Gd and T1WCD data points is moderate indicating
some deviation from the best-fit line. The correlation between
Gd in the T1W post-Gd and verteporfin indicates that contrast-
enhanced MRI could be a potential surrogate for dosimetry mea-
surements, treatment planning, and guidance of fiber placement.
Although the image contrast between the tumor and normal tis-
sue in the T1WCD is enhanced due to the subtraction of the
nonenhancing regions, the correlation is not as strong as seen
in the T1W post-Gd images. This is likely due to the increased
error in the difference image, as compared to the individual pre-
and post-Gd images. Attempts at correlating the different high-
lighting regions (i.e., outer edge versus center of tumor) were not
possible in this study due to the large differences in image res-
olution between the MR and fluorescence images and the lack of
true pixel-by-pixel image registration. Anecdotally, the hetero-
geneous pattern of both fluorescence and Gd enhancement can
be observed in Fig. 2 where there is significant highlighting of
the outer edges of the tumor in both the T1W post-Gd and ver-
teporfin fluorescence images, but not the center of the tumor,
which has a high propensity to be necrotic.5
There was no proportional correlation (r ¼ 0.065, RMSE ¼
38) observed between verteporfin fluorescence and the T1W
pre-Gd MR image [Fig. 3(a)] even though the RMSE is low,
indicating that the data was closely related to the best-fit
line. This was expected, as T1W images without contrast
enhancement will display areas with similar protein content
as having homogeneous intensity and is further demonstrated
by near zero slope and narrow confidence intervals. In addition,
a weak, negative linear correlation and a high RMSE (r ¼
−0.18, RMSE ¼ 294) were observed between verteporfin fluo-
rescence and T2W MR images [Fig. 3(d)]. Even though all
points lie within the 95% predication limits on the linear regres-
sion, the spread is much wider than in any of the other image
comparisons. T2W MR images highlight free water within tis-
sue; therefore edemic regions, that tend to be necrotic in this
case, will be highlighted but do not accumulate contrast agents.
This is illustrated well in Fig. 1 where the center of the tumor has
higher intensity in the T2W image [Fig. 1(e)] but remains non-
enhanced in the Gd contrast images [Figs. 1(c) and 1(d)].
Inaccuracies in the ex vivo alignment of the sliced tumor tis-
sue with in vivo images may have caused errors in the reported
correlations. It is unlikely that this error in correlation is due to
large tumor tissue deformation as the AsPC-1 orthotopic tumors
are quite firm. It is more likely that rotational errors occurred
during tissue removal or an alignment error on the MR
scans. However, only bulk average intensities were used here,
such that errors in image alignment, tissue deformation, or tissue
rotation would be small. These errors could be reduced in the
future by freezing, slicing, and imaging the whole mouse abdo-
men ex vivo. It would be advantageous in future studies to cor-
relate histological features with verteporfin uptake. In vivo MRI
scans have been accurately correlated to ex vivo histology using
an intermediate MRI scan ex vivo excised tissue and rigorous
Fig. 1 Magnetic resonance imaging (MRI) scans of orthotopic AsPC-
1 tumors. (a) A T2W coronal scan was used to determine tumor posi-
tion and align axial slice markers for tumor slices of interest. The bold
dashed line (white) is the “tumor origin” and the smaller dashed lines
(red) are a representation of the 1-mm image slices, not drawn to
scale. The axial image slices are used for analysis, and a single
slice is shown for each scan type: (b) T1W pre-gadolinium (Gd) ad-
ministration, (c) T1W post-Gd, (d) T1W contrast difference, and
(e) T2W.
Fig. 2 A representative tumor slice is shown to demonstrate region of
interest (ROI, red dashed line) selection. A 4-μm H&E section (a) is
used to distinguish the tumor and then transferred to the ex vivo fluo-
rescence image of verteporfin (b) and one of the four MR images,
T1W post-Gd is used for demonstration (c).
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registration algorithms,7–9 and it would be valuable to extend
these techniques to fluorescence imaging. Additionally, admin-
istrating Magnevist® and verteporfin by intravascular injection
may increase the spatial correlation. Taking into consideration
the distribution time for each agent minimized the effect of the
different routes of administration (i.e., 10 and 60 min for verte-
porfin and Magnevist®, respectively).
Correlating accumulation of verteporfin and Gd within the
tumor tissue shows promise as a new method for surrogate
dosimetry for PaC. However, these trends may not extend to
other photosensitizers, depending on the inherent vascular
dynamics. Additionally, the patient flow in the VERTPAC
study utilizes computed tomography (CT) contrast to locate
the tumor and plan fiber placement for therapy, not MR contrast.
Parallel efforts within our laboratory have used tissue properties
derived from the treatment planning CT scans and simulations
of the correlating light dose to predict necrotic volumes in
patients post-therapy.10 The feasibility of repeating the study
presented here using a clinical contrast CT for surrogate dosim-
etry is low due to the poor resolution and sensitivity of whole
body CT in the murine model. Therefore, a VX2 pancreas tumor
model in rabbits was developed,11 and ongoing studies are being
performed using a clinical CT scanner and i.v. administered
Omnipaque™ to extend this promising dosimetry technique
into clinical practice.
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Fig. 3 Linear regressions and Pearson correlation coefficients (r ) indicate that BPD fluorescence has no
correlation with (a) T1W pre-gadolinium (Gd), (b) a strong, positive correlation with T1W post-Gd, (c) a
medium positive correlation with T1W contrast difference, and (d) a weak negative correlation with T2W.
Root-mean squared error (RMSE) is reported in arbitrary units of intensity. Black squares: individual
slices from each animal; solid red line: best-fit line; dashed green lines: 95% confidence limit; and dotted
blue line: 95% prediction limit.
Journal of Biomedical Optics 120504-3 December 2013 • Vol. 18(12)
JBO Letters
